Form 4: OrbiMed Advisors Sells NeuroPace Inc (NPCE) Shares in Multiple Transactions

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has sold a portion of its common stock holdings in a series of transactions between April 16 and April 18, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VI LLC, filed a Form 4 detailing changes in beneficial ownership of NeuroPace Inc (NPCE) common stock.
• The transactions involved the sale of NeuroPace shares on April 16, 17, and 18, 2024.
• On April 16, 2024, 14,069 shares were sold at a price of $14.01 per share.
• On April 17, 2024, 300 shares were sold at a price of $14.15 per share.
• On April 18, 2024, 2,623 shares were sold at a price of $14.06 per share.
• Following these transactions, OrbiMed Advisors indirectly holds 3,501,975 shares of NeuroPace Inc common stock.
• The shares are held of record by OrbiMed Private Investments VI, LP (OPI VI), with OrbiMed Capital GP VI LLC (GP VI) as the general partner and OrbiMed Advisors LLC as the managing member of GP VI.
• OrbiMed Advisors disclaims beneficial ownership of the securities except to the extent of its pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock sales. It doesn't inherently indicate positive or negative sentiment, but rather a transactional disclosure.

Risks

• The sale of shares by a major shareholder like OrbiMed Advisors could potentially exert downward pressure on the stock price of NeuroPace Inc.

Industry Context

Venture capital and private equity firms like OrbiMed Advisors often adjust their holdings in portfolio companies as part of their investment strategy. These transactions are common and can be driven by various factors, including fund lifecycle, investment performance, and market conditions.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's share sales, potentially influencing the stock price in the short term.

Key Dates